30.67
전일 마감가:
$29.33
열려 있는:
$29.77
하루 거래량:
5.64M
Relative Volume:
4.10
시가총액:
$19.68B
수익:
$2.62B
순이익/손실:
$966.70M
주가수익비율:
20.44
EPS:
1.5004
순현금흐름:
$1.09B
1주 성능:
+6.75%
1개월 성능:
+23.32%
6개월 성능:
+56.64%
1년 성능:
+25.80%
Genmab Adr Stock (GMAB) Company Profile
GMAB을(를) 다른 주식과 비교
주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
---|---|---|---|---|---|---|
![]()
GMAB
Genmab Adr
|
30.67 | 18.05B | 2.62B | 966.70M | 1.09B | 1.5004 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
391.64 | 101.35B | 11.39B | 3.64B | 3.50B | 13.99 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
456.00 | 58.66B | 2.46B | -319.09M | -52.09M | -2.47 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
562.27 | 59.43B | 14.21B | 4.46B | 3.56B | 39.68 |
![]()
ARGX
Argen X Se Adr
|
737.56 | 44.01B | 3.06B | 1.28B | 447.35M | 21.30 |
![]()
ONC
Beone Medicines Ltd Adr
|
340.70 | 36.56B | 3.81B | -644.79M | -669.77M | -6.24 |
Genmab Adr Stock (GMAB) Upgrades & Downgrades
날짜 | 액션 | 분석자 | 등급 변경 |
---|---|---|---|
2025-09-23 | 업그레이드 | Guggenheim | Neutral → Buy |
2025-04-01 | 다운그레이드 | Bernstein | Mkt Perform → Underperform |
2025-03-11 | 업그레이드 | William Blair | Mkt Perform → Outperform |
2025-02-13 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
2024-10-08 | 개시 | Redburn Atlantic | Buy |
2024-09-04 | 재개 | Morgan Stanley | Equal-Weight |
2024-08-20 | 다운그레이드 | JP Morgan | Overweight → Neutral |
2024-07-15 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
2024-02-23 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
2024-01-22 | 다운그레이드 | Citigroup | Neutral → Sell |
2023-12-06 | 업그레이드 | UBS | Neutral → Buy |
2023-11-10 | 업그레이드 | Deutsche Bank | Hold → Buy |
2023-11-08 | 업그레이드 | DNB Markets | Sell → Buy |
2023-10-18 | 개시 | Exane BNP Paribas | Underperform |
2023-09-06 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
2023-08-24 | 개시 | BTIG Research | Buy |
2023-07-14 | 개시 | HSBC Securities | Buy |
2023-05-31 | 개시 | UBS | Neutral |
2023-05-12 | 개시 | Morgan Stanley | Underweight |
2022-12-20 | 다운그레이드 | Citigroup | Buy → Neutral |
2022-11-14 | 개시 | William Blair | Mkt Perform |
2022-11-11 | 다운그레이드 | Deutsche Bank | Buy → Hold |
2022-06-24 | 개시 | BMO Capital Markets | Market Perform |
2022-05-02 | 개시 | Cowen | Market Perform |
2022-03-16 | 업그레이드 | UBS | Neutral → Buy |
2022-01-31 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
2022-01-03 | 다운그레이드 | Guggenheim | Buy → Neutral |
2021-12-01 | 개시 | Berenberg | Sell |
2021-09-16 | 다운그레이드 | Jefferies | Buy → Hold |
2021-09-07 | 다운그레이드 | Morgan Stanley | Equal-Weight → Underweight |
2021-08-24 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
2021-04-20 | 개시 | Deutsche Bank | Buy |
2021-01-19 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
2020-09-23 | 다운그레이드 | Bryan Garnier | Neutral → Sell |
2020-09-08 | 개시 | SVB Leerink | Mkt Perform |
2020-06-25 | 다운그레이드 | Credit Suisse | Outperform → Neutral |
2020-04-23 | 개시 | Credit Suisse | Outperform |
2020-02-24 | 재확인 | H.C. Wainwright | Buy |
2020-01-13 | 개시 | SunTrust | Buy |
2019-12-12 | 다운그레이드 | Deutsche Bank | Buy → Hold |
2019-09-13 | 업그레이드 | BofA/Merrill | Neutral → Buy |
2019-09-12 | 업그레이드 | JP Morgan | Neutral → Overweight |
2019-08-12 | 개시 | Guggenheim | Buy |
2019-08-12 | 개시 | Morgan Stanley | Overweight |
2019-08-12 | 개시 | RBC Capital Mkts | Outperform |
모두보기
Genmab Adr 주식(GMAB)의 최신 뉴스
Park Avenue Securities LLC Acquires 832 Shares of Genmab A/S Sponsored ADR $GMAB - Defense World
TD Private Client Wealth LLC Has $130,000 Stock Holdings in Genmab A/S Sponsored ADR $GMAB - Defense World
Genmab A/S (NASDAQ:GMAB) Sees Strong Trading Volume on Analyst Upgrade - Defense World
Genmab A/S (NASDAQ:GMAB) Sees Large Volume Increase After Analyst Upgrade - MarketBeat
Genmab Makes $8 Billion Bet On Merus With Potential Cancer Breakthrough - Benzinga
European Stocks Higher to Kick Off the Week - TradingView
Genmab A/S Sponsored ADR $GMAB Shares Sold by Fifth Third Bancorp - Defense World
Before the bell: futures up, Lufthansa cuts jobs, GSK CEO steps down - TradingView
Genmab to Acquire Merus, Expanding Late-Stage Pipeline and Accelerating into a Wholly Owned Model - Placera.se
Genmab A/S (NASDAQ:GMAB) Upgraded by Guggenheim to Buy Rating - Defense World
Genmab A/S Sponsored ADR $GMAB Shares Purchased by Parallel Advisors LLC - Defense World
Rhumbline Advisers Increases Stock Holdings in Genmab A/S Sponsored ADR $GMAB - Defense World
Genmab A/S Sponsored ADR (NASDAQ:GMAB) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
Genmab A/S (NASDAQ:GMAB) Hits New 12-Month High Following Analyst Upgrade - Defense World
Genmab A/S (NASDAQ:GMAB) Sets New 52-Week High Following Analyst Upgrade - MarketBeat
Foresight Group Ltd Liability Partnership Takes Position in Genmab A/S Sponsored ADR $GMAB - MarketBeat
Vident Advisory LLC Buys Shares of 12,377 Genmab A/S Sponsored ADR $GMAB - MarketBeat
Weekly Stock Grader Analysis: Upgrades & Downgrades on Top Blue-Chip Stocks - InvestorPlace
Scientech Research LLC Increases Stake in Genmab A/S Sponsored ADR $GMAB - MarketBeat
Genmab A/S (NASDAQ:GMAB) Sets New 1-Year HighStill a Buy? - MarketBeat
Northern Trust Corp Raises Position in Genmab A/S Sponsored ADR $GMAB - MarketBeat
Genmab A/S Sponsored ADR $GMAB Shares Sold by Alliancebernstein L.P. - MarketBeat
Graham Capital Management L.P. Acquires 16,035 Shares of Genmab A/S Sponsored ADR $GMAB - MarketBeat
Cubist Systematic Strategies LLC Grows Holdings in Genmab A/S Sponsored ADR $GMAB - MarketBeat
Orbis Allan Gray Ltd Has $111.82 Million Stake in Genmab A/S Sponsored ADR $GMAB - MarketBeat
Synovus Financial Corp Takes $633,000 Position in Genmab A/S Sponsored ADR $GMAB - MarketBeat
Tema Etfs LLC Boosts Stake in Genmab A/S Sponsored ADR $GMAB - MarketBeat
Cresset Asset Management LLC Has $244,000 Position in Genmab A/S Sponsored ADR $GMAB - MarketBeat
Cresset Asset Management LLC Has $244,000 Stock Position in Genmab A/S Sponsored ADR $GMAB - Defense World
Genmab A/S Sponsored ADR (NASDAQ:GMAB) Given Average Rating of “Moderate Buy” by Brokerages - Defense World
Genmab A/S (NASDAQ:GMAB) Cut to Hold at Zacks Research - Defense World
IBD Rating Upgrades: MINISO Group Holding ADR Flashes Improved Technical Strength - inkl
IBD Rating Upgrades: Genmab ADR Shows Improved Relative Price Strength - Investor's Business Daily
Biotech Stocks To Watch And Pharma Industry News - Investor's Business Daily
IBD Rating Upgrades: Applied Indl Techs Shows Improved Relative Price Strength - inkl
What is HC Wainwright’s Forecast for Genmab A/S Q1 Earnings? - Defense World
IBD Rating Upgrades: HCA Healthcare Shows Improved Technical Strength - inkl
Genmab A/S Sponsored ADR (NASDAQ:GMAB) Shares Purchased by LPL Financial LLC - Defense World
What is William Blair’s Forecast for Genmab A/S Q3 Earnings? - Defense World
Wall Street Analysts Believe Genmab (GMAB) Could Rally 33.8%: Here's is How to Trade - MSN
Genmab and BioNTech’s Innovative Cancer Trial: A Market Game Changer? - The Globe and Mail
BioNTech and Genmab’s Promising Colorectal Cancer Study: A Potential Game-Changer? - TipRanks
GMAB: Riding the Market Waves of Growth and Decline in 2025 - investchronicle.com
Genmab Adr (GMAB) 재무 분석
매출
순이익
현금흐름
주당 순 이익
자본화:
|
볼륨(24시간):